A carregar...
Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
KRAS mutations represent one of the most prevalent oncogenic driver mutations in non-small cell lung cancer (NSCLC). For many years we have unsuccessfully addressed KRAS mutation as a unique disease. The recent widespread use of comprehensive genomic profiling has identified different subgroups with...
Na minha lista:
| Publicado no: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5564881/ https://ncbi.nlm.nih.gov/pubmed/29081842 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834017719829 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|